welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

BioMarin snags cash as Sarepta skips Duchenne patent battle

Sarepta Therapeutics Inc. agreed to pay $35 million plus royalties and potential milestones to BioMarin Pharmaceutical Inc. to resolve a dispute over patents on its Duchenne muscular dystrophy drug.

Sarepta said Tuesday it had reached an agreement to license the intellectual property of San Rafael-based BioMarin, which had challenged key patents covering Sarepta’s approved Duchenne drug, Exondys 51 as well as other so-called “exon-skipping” treatments.

BioMarin Snags Cash As Sarepta Skips Duchenne Patent Battle